[A16-66] Elotuzumab (multiple myeloma) - Addendum to Commission A16-32
Last updated 01.12.2016
Commission awarded on 11.10.2016 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.